CBEE Seminar: Dipanjan Pan, PhD, FRSC, FAHA, FACC
Molecular Med. from Advanced Imaging to Therapy & Biosensing
Location
Information Technology/Engineering : 456
Date & Time
April 17, 2019, 9:00 am – 10:00 am
Description
Title:
Molecular Medicine from Advanced Imaging to Therapy and Biosensing
Speaker:
Dipanjan Pan, PhD, FRSC, FAHA, FACC
Associate Professor and Associate Head of Graduate Program
Co-Director, Respiratory, Carle Illinois College of Medicine
Bioengineering, Materials Science and Engineering, Beckman Institute and College of Medicine, University of Illinois at Urbana-Champaign
Key words:
nanomedicine, drug discovery, drug delivery, molecular imaging, biosensing
Abstract:
Pan-Lab@UIUC develops next generation translatable technologies to improve human health by uniquely merging ‘molecule making’ and ‘device making’ through innovations in nanomedicine, point-of-care biosensing and machine learning tools.1-7 Nanoscale structures offer unprecedented potential in pre-emptive medicine covering early detection, diagnosis and therapy of diseases. They bring the ability to specifically tailor the biological response and long term fate of therapeutic molecules avoiding off-target side effects. This talk will address the promise and perils in nanomedicine and introduce defined approaches for next generation particles that completely ‘disappears’ from body. We will briefly introduce novel multi-color, ‘luminescence switachable’ carbon nanodots4 and other ‘soft’ nano-platforms developed in our laboratories and highlight seminal results from preclinical imaging studies, e.g. targeting angiogenic sparse biological epitopes, microbiota detection and treatment strategies for hemorrhagic shock or cancer stem cells2.
In the later part of the talk we will introduce a multi-modal image-guided treatment strategy for hepatocellular carcinoma using photon counting CT and spatially-tracked 3D ultrasound imaging with catheter-based therapeutic device to deliver in combination with prodrug.7 In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand.3 Its efficacy, safety and drug metabolism is demonstrated in xenografted rodent and transgenic oncopig models of liver cancer also revealing surprising immunomodulation through programmed death-ligand-1 pathway.